Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)

March 27, 2019

Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia

LEXINGTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced that posters featuring ex vivo and in-human data supporting Microbiome Metabolic Therapy (MMT™) programs for the treatment of hyperammonemia have been accepted for presentation at the Society for Inherited Metabolic Disorders 41st Annual Meeting, and The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of Liver (EASL). 

Society for Inherited Metabolic Disorders 41st Annual Meeting
April 6-9, 2019; Seattle, Washington
Poster Title: KB195, a Novel Glycan, Modulates Ammonia Metabolism in Healthy Subjects and in Microbiome Samples Collected From Patients With Urea Cycle Disorders (UCD)
Poster Session: Sunday, April 7, 2019 from 7:15-10:00 pm PT

The International Liver Congress 2019 (EASL)
April 10-14, 2019; Vienna, Austria
Poster Title: Identification of Novel Glycans That Target Gut Microbiota-Associated Ammonia Production
Poster Session: Friday, April 12, 2019, from 9:00 am-5:00 pm CET

Kaleido intends to make the posters available following the presentations on its website at https://kaleido.com/platform/#publications.

Kaleido has built a human-centric proprietary product platform to discover and develop novel MMTs designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. The Company is advancing MMT candidates for the treatment of hyperammonemia in patients with UCD and in patients with hepatic encephalopathy. Kaleido has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to initiate a Phase 2 clinical trial of KB195 in UCD and expects enrollment to begin during the first half of 2019. The Company has also initiated non-IND clinical studies evaluating KB195 in patients with UCD and KB174 in patients with cirrhosis.

About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential of our MMT candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the non-IND clinical study for KB195 in patients with UCD, the non-IND clinical study for KB174 in patients with cirrhosis as well as the non-IND clinical study of KB174 in healthy volunteers to study dosing, including statements regarding the timing for receipt of data from such studies and potential future studies, the clinical development and safety profile of our MMT candidates and their therapeutic potential, whether and when, if at all, our MMT candidates will receive approval form the U.S. Food and Drug Administration and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our final prospectus for our initial public offering, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Contact
Amy Reilly
617-890-5721
amy.reilly@kaleido.com

Kaleido_rgb_300dpi.jpg

Source: Kaleido Biosciences

Print Page
Email Alerts
RSS
Investor Contact
Search